BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 36631830)

  • 1. Elevated neurofilament light chain CSF/serum ratio indicates impaired CSF outflow in idiopathic intracranial hypertension.
    Engel S; Halcour J; Ellwardt E; Uphaus T; Steffen F; Zipp F; Bittner S; Luessi F
    Fluids Barriers CNS; 2023 Jan; 20(1):3. PubMed ID: 36631830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurofilament light chain marks severity of papilledema in idiopathic intracranial hypertension.
    Knoche T; Gaus V; Haffner P; Kowski A
    Neurol Sci; 2023 Jun; 44(6):2131-2135. PubMed ID: 36689008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis.
    McComb M; Krikheli M; Uher T; Browne RW; Srpova B; Oechtering J; Maceski AM; Tyblova M; Jakimovski D; Ramasamy DP; Bergsland N; Krasensky J; Noskova L; Fialova L; Weinstock-Guttman B; Havrdova EK; Vaneckova M; Zivadinov R; Horakova D; Kuhle J; Ramanathan M
    J Clin Lipidol; 2020; 14(5):675-684.e2. PubMed ID: 32758395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma and cerebrospinal fluid concentrations of neurofilament light protein correlate in patients with idiopathic normal pressure hydrocephalus.
    Jeppsson A; Sandelius Å; Zettergren A; Kern S; Skoog I; Blennow K; Zetterberg H; Wikkelsø C; Hellström P; Tullberg M
    Fluids Barriers CNS; 2023 Jul; 20(1):54. PubMed ID: 37415175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low cerebrospinal fluid protein in prepubertal children with idiopathic intracranial hypertension.
    Margeta MA; Buckley EG; El-Dairi MA
    J AAPOS; 2015 Apr; 19(2):135-9. PubMed ID: 25828820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model.
    Yeo T; Bayuangga H; Augusto-Oliveira M; Sealey M; Claridge TDW; Tanner R; Leppert D; Palace J; Kuhle J; Probert F; Anthony DC
    J Neuroinflammation; 2022 Oct; 19(1):252. PubMed ID: 36210459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients.
    Sejbaek T; Nielsen HH; Penner N; Plavina T; Mendoza JP; Martin NA; Elkjaer ML; Ravnborg MH; Illes Z
    J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1324-1330. PubMed ID: 31611264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease.
    Peng L; Bi C; Xia D; Mao L; Qian H
    Mult Scler Relat Disord; 2019 May; 30():123-128. PubMed ID: 30771578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS.
    Halbgebauer S; Steinacker P; Verde F; Weishaupt J; Oeckl P; von Arnim C; Dorst J; Feneberg E; Mayer B; Rosenbohm A; Silani V; Ludolph AC; Otto M
    J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):68-74. PubMed ID: 34417339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ratio and index of Neurofilament light chain indicate its origin in Guillain-Barré Syndrome.
    Körtvelyessy P; Kuhle J; Düzel E; Vielhaber S; Schmidt C; Heinius A; Leypoldt F; Schraven B; Reinhold D; Leppert D; Goihl A
    Ann Clin Transl Neurol; 2020 Nov; 7(11):2213-2220. PubMed ID: 33030817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship of cerebrospinal fluid neurofilament levels with magnetic resonance imaging lesion location and disease activity in multiple sclerosis.
    Adams A; Tilden W; Bestwick J; Holden D; Bianchi L; Smets I; Giovannoni G; Gnanapavan S
    Eur J Neurol; 2022 Sep; 29(9):2754-2760. PubMed ID: 35615966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Pre-Lumbar puncture Intracranial Hypertension Scale (PLIHS): A practical scale to identify subjects with normal cerebrospinal fluid pressure in the management of idiopathic intracranial hypertension.
    Raggi A; Bianchi Marzoli S; Ciasca P; Cammarata G; Melzi L; Chiapparini L; Erbetta A; Ciceri E; Faragò G; Gioppo A; Usai S; D'Amico D
    J Neurol Sci; 2021 Oct; 429():118058. PubMed ID: 34461550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retinol-binding protein and retinol analysis in cerebrospinal fluid and serum of patients with and without idiopathic intracranial hypertension.
    Warner JE; Larson AJ; Bhosale P; Digre KB; Henley C; Alder SC; Katz BJ; Bernstein PS
    J Neuroophthalmol; 2007 Dec; 27(4):258-62. PubMed ID: 18090557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid total protein in idiopathic intracranial hypertension.
    Berezovsky DE; Bruce BB; Vasseneix C; Peragallo JH; Newman NJ; Biousse V
    J Neurol Sci; 2017 Oct; 381():226-229. PubMed ID: 28991687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis.
    Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
    J Neuroinflammation; 2018 Jul; 15(1):209. PubMed ID: 30021640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of neurofilament light chain in the cerebrospinal fluid and blood as a biomarker for neuronal damage in experimental pneumococcal meningitis.
    Le ND; Muri L; Grandgirard D; Kuhle J; Leppert D; Leib SL
    J Neuroinflammation; 2020 Oct; 17(1):293. PubMed ID: 33028339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.
    Watanabe M; Nakamura Y; Michalak Z; Isobe N; Barro C; Leppert D; Matsushita T; Hayashi F; Yamasaki R; Kuhle J; Kira JI
    Neurology; 2019 Sep; 93(13):e1299-e1311. PubMed ID: 31471502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitation of neurofilament light chain protein in serum and cerebrospinal fluid from patients with multiple sclerosis using the MSD R-PLEX NfL assay.
    Ulndreaj A; Sohaei D; Thebault S; Pons-Belda OD; Fernandez-Uriarte A; Campbell C; Cheo D; Stengelin M; Sigal G; Freedman MS; Scarisbrick IA; Prassas I; Diamandis EP
    Diagnosis (Berl); 2023 Aug; 10(3):275-280. PubMed ID: 36788117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosis.
    Koerbel K; Maiworm M; Schaller-Paule M; Schäfer JH; Jakob J; Friedauer L; Steffen F; Bittner S; Foerch C; Yalachkov Y
    Mult Scler Relat Disord; 2024 Apr; 87():105644. PubMed ID: 38701697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.